72531-23-8

Basic information

• Product Name: 1-(4-Amino-3-chloro-phenyl)-ethanone
• Synonyms: 1-(4-AMINO-3-CHLORO-PHENYL)-ETHANONE;4'-Amino-2'-chloroacetophenone
• CAS NO: 72531-23-8
• Molecular Formula: C₈H₈ClNO
• Molecular Weight: 169.61
• Mol File: 72531-23-8.mol

Chemical Properties

• Boiling Point: 304.1 °C at 760 mmHg
• Flash Point: 137.7 °C
• Appearance: /
• Density: 1.254 g/cm³
• PKA: 1.11±0.10(Predicted)
• CAS DataBase Reference: 1-(4-Amino-3-chloro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Amino-3-chloro-phenyl)-ethanone(72531-23-8)
• EPA Substance Registry System: 1-(4-Amino-3-chloro-phenyl)-ethanone(72531-23-8)

Safety Data

• Hazardous Substances Data: 72531-23-8(Hazardous Substances Data)

Usage

Uses

1-(4-Amino-3-chlorophenyl)ethanone is an intermediate to many COX-II selective inhibitors.

Upstream product

• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 
• 67818-41-1 1-(2-chloro-4-nitrophenyl)ethanone 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 588-07-8 3-Chloroacetanilide 
• 103273-72-9 acetic acid-(4-acetyl-3-chloro-anilide) 

Downstream Products

• 1134916-47-4 1-(2-chloro-4-diallylamino-phenyl)-ethanone 

Relevant articles and documents

Heterocyclic Compounds and Methods of Use

This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists. Compounds of the invention may also find use in treating cancer. Presented herein are novel compounds bearing a perhaloalkylsulfonamide moiety. Such compounds, in addition to being highly effective SREBP inhibitors, are also unexpectedly highly bioavailable in vivo. Heteroaromatic compounds bearing sulfonamide groups are prone to several ionic states, based on the inherent pKa values.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.

1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS

The present invention relates to compounds of formula I wherein R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

GLUCOCORTICOID RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula I wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucoc

Process for the preparation of fluoroaromatic and fluoroheteroaromatic compounds

Good yields of a range of fluoroaromatic and fluoroheteroaromatic compounds may be obtained by reacting an aromatic or a heteroaromatic amine with a nitrosyl polyfluoro salt in an inert solvent to form an intermediate aryl or heteroaryl diazonium polyfluoro salt and decomposing this aryl or heteroaryl diazonium polyfluoro salt in situ. The process described is especially suitable for the preparation in good yield of fluoroaromatic and fluoroheteroaromatic compounds with ortho substituents.